Ligand Pharmaceuticals Inc (LGND) stock
Close on Nov 17, 2026Market cap $5.88BP/E 128.3Yield –
Ligand Pharmaceuticals Inc grew revenue 1.0% to $253.83M over the twelve months to Sep 30, 2026. Operating income rose 41.9% to $25.52M, moving the operating margin from 7.2% to 10.1%. Free cash flow was $90.63M, up 194.6% from a year earlier. At the latest close the market valued the company at $5.88B, 128.3 times its earnings.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2026
Valuation
- Market cap
- $5.88B
- P/E ratio
- 128.3
- Price to sales
- 23.15
- Price to book
- 6.11
- Dividend yield
- –
- Free cash flow yield
- 1.54%
Fundamentals
- Revenue
- $253.83M
- Net income
- $51.46M
- EPS, diluted
- $2.29
- Free cash flow
- $90.63M
- Book value per share
- $48.18
- Diluted shares
- 20M
Trading
- Next earnings
- Feb 25, 2027 (estimated, before the open)
- Previous close
- $301.71
- Open
- $300.26
- Day's range
- $291.61 – $302.02
- Volume
- 293,655
- Average volume (20 days)
- 224,253
- Index membership
- S&P SmallCap 600 (since Nov 2021), Russell 2000, Russell 3000
- 52-week range
- $175.89 – $326.63
- RSI (14 days)
- 45.8
- Volatility (1 year)
- 36.6%
- Relative volume
- 0.78×
On 1 of our idea list: Institutions accumulating
Index membership is inferred from the holdings of funds that track each index (SPSM, IJR, IWM, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2010, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 17, 2026. The S&P 500 is measured by the SPY fund.
| Period | LGND | S&P 500 | Difference | LGND per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -0.6% | -4.0% | +3.5 pts | ||
| 3 months | +0.7% | -5.0% | +5.7 pts | ||
| Year to date | +55.4% | +8.2% | +47.2 pts | ||
| 1 year | +45.9% | +11.2% | +34.7 pts | ||
| 3 years | +408.1% | +68.5% | +339.7 pts | +71.9% | +19.0% |
| 5 years | +190.7% | +67.3% | +123.4 pts | +23.8% | +10.8% |
| 10 years | +346.3% | +291.6% | +54.6 pts | +16.1% | +14.6% |
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Ligand Pharmaceuticals filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Update
- Update
- Results
- Update
- News
About Ligand Pharmaceuticals
Pharmaceutical Preparations
Ligand Pharmaceuticals is a biopharmaceutical company focused on developing and licensing biopharmaceutical assets, royalty assets, and related technologies. Its business model centers on acquiring, creating, and managing financial and intangible royalty rights across various drug development programs and partnered commercial therapies, alongside selling proprietary materials such as Captisol. The company enters into development and licensing agreements, service contracts, and collaborative partnerships with global biopharmaceutical firms and research partners to advance clinical-stage candidates and marketed products.
Company profile, executives and historyLigand Pharmaceuticals stock: common questions
What is Ligand Pharmaceuticals's stock price?
LGND closed at $293.81 on Nov 17, 2026, down 2.62% on the day. Over the past 52 weeks it traded between $175.89 and $326.63.
What is Ligand Pharmaceuticals's market cap?
Ligand Pharmaceuticals was worth $5.88B at the close on Nov 17, 2026: the share price times the diluted shares outstanding.
What is LGND's P/E ratio?
LGND trades at 128.3 times earnings, based on diluted earnings per share of $2.29 over the twelve months to Sep 30, 2026.
How much revenue does Ligand Pharmaceuticals make?
Ligand Pharmaceuticals reported revenue of $253.83M for the twelve months to Sep 30, 2026, up 1.0% from a year earlier.
Does Ligand Pharmaceuticals pay a dividend?
No. Ligand Pharmaceuticals has not paid a cash dividend over the last twelve months.
When does Ligand Pharmaceuticals report earnings next?
Ligand Pharmaceuticals is expected to report Q4 FY2026 results on Feb 25, 2027, before the open. The date is estimated from its past reporting pattern until the company confirms it.
How has LGND stock performed over the past year?
Including dividends, LGND returned +45.9% over the past year, against +11.2% for the S&P 500.
Who are Ligand Pharmaceuticals's competitors?
Companies most similar to Ligand Pharmaceuticals by business, industry and size include KPTIQ, AAPG, ANAB, AMRN, SDGR.
See a number that looks wrong?